Extended Data Fig. 6. HDAC6 scores in other human cancers.

(a) Correlation between HDAC6 regulon in different tumor types. The tumors sets are the same as in figure 4c. The number of patient sample for each set is indicated there. LAML: Acute Myeloid Leukemia; LIHC: Liver Hepatocellular Carcinoma; UVM: Uveal Melanoma; KIRP: Kidney Renal Papillary Cell Carcinoma; PCPG: Pheochromocytoma and Paraganglioma; DLBC: Diffuse Large B-Cell Lymphoma; ACC: Adrenocortical Carcinoma; UCS: Uterine Carcinosarcoma; KIRC: Kidney Renal Clear Cell Carcinoma; THYM: Thymoma; CHOL: Cholangiocarcinoma; SKCM: Skin Cutaneous Melanoma; CRC: Colorectal Carcinoma; LGG: Brain Lower Grade Glioma; UCEC: Uterine Corpus Endometrial Carcinoma; KICH: Kidney Chromophobe; MESO: Mesothelioma; TGCT: Testicular Germ Cell Tumors; GBM: Glioblastoma; PRAD: Prostate Adenocarcinoma; CESC: Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma; BLCA: Bladder Urothelial Carcinoma; SARC: Sarcoma; OV: Ovarian Serous Cystadenocarcinoma; THCA: Thyroid Carcinoma; ESCA: Esophageal Carcinoma; BRCA: BC; LUAD: Lung Adenocarcinoma; HNSC: Head and Neck Squamous Cell Carcinoma; PAAD: Pancreatic Adenocarcinoma; STAD: Stomach Adenocarcinoma; LUSC: Lung Squamous Cell Carcinoma. P value was estimated by two-tailed Fisher’s exact test. (b) List with all the cell lines evaluated by dose-response to ricolinostat and HDAC6 scores. The correlation (R) and P value between the response to ricolinostat and HDAC6 scores were estimated by two-tailed Spearman correlation test. (c) Graphic showing the correlation between the HDAC6 score and the response to ricolinostat in individual cell types (only tumor types with more than 6 cell lines are shown). N=8 individual independent experiments for each ricolinostat dose. The curve was fitted by stat_smooth algorithsm using lm smoothing method and y~log2(x) formula.